

For Immediate Release

September 2007 – Phase 2 Clinical Trial in Acne Vulgaris Begins Enrollment

AndroScience Corporation (ASC), a San Diego-based biotech company, is developing ASC-J9 as a topical agent for the treatment of acne. Two Phase 1 human clinical trials have already been successfully completed.

Enrollment in a Phase 2 randomized, double-blinded, placebo-controlled 12-week dose-ranging study began in September 2007. The purpose of this Phase 2 study is to evaluate the safety and efficacy of ASC-J9 as a topical cream treatment of acne vulgaris.

Any patients with facial acne interested in enrolling in the study may contact Gloria Gosse at 201-587-0500, Ext. 3333.